Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Hepatocellular carcinoma (HCC) developed in fibrotic liver does not respond well to immunotherapy, mainly due to the stromal microenvironment and the fibrosis-related immunosuppressive factors. The characteristic of liver sinusoidal endothelial cells (LSECs) in contributing to fibrosis and orchestrating immune response is responsible for the refractory to targeted therapy or immunotherapy of HCC. We aim to seek a new strategy for HCC treatment based on an old drug simvastatin which shows protecting effect on LSEC. Method: The features of LSECs in mouse fibrotic HCC model and human HCC patients were identified by immunofluorescence and scanning electron microscopy. The effect of simvastatin on LSECs and hepatic stellate cells (HSCs) was examined by immunoblotting, quantitative RT-PCR and RNA-seq. LSEC-targeted delivery of simvastatin was designed using nanotechnology. The anti-HCC effect and toxicity of the nano-drug was evaluated in both intra-hepatic and hemi-splenic inoculated mouse fibrotic HCC model. Results: LSEC capillarization is associated with fibrotic HCC progression and poor survival in both murine HCC model and HCC patients. We further found simvastatin restores the quiescence of activated hepatic stellate cells (aHSCs) via stimulation of KLF2-NO signaling in LSECs, and up-regulates the expression of CXCL16 in LSECs. In intrahepatic inoculated fibrotic HCC mouse model, LSEC-targeted nano-delivery of simvastatin not only alleviates LSEC capillarization to regress the stromal microenvironment, but also recruits natural killer T (NKT) cells through CXCL16 to suppress tumor progression. Together with anti-programmed death-1-ligand-1 (anti-PD-L1) antibody, targeted-delivery of simvastatin achieves an improved therapeutic effect in hemi-splenic inoculated advanced-stage HCC model. Conclusions: These findings reveal an immune-based therapeutic mechanism of simvastatin for remodeling immunosuppressive tumor microenvironment, therefore providing a novel strategy in treating HCC. Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the upregulation of CXCL16 in LSECs through the administration of simvastatin-loaded nanoparticles in mice leads to reduced LSEC capillarization and the recruitment of NKT cells to suppress tumor progression [331], suggesting that LSECs are promising therapeutic targets.”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [331]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown
Pertea, M., Kim, D., Pertea, G. M., Leek, J. T., & Salzberg, S. L. (2016) · Nature Protocols · doi:10.1038/nprot.2016.095 · Cited by 6,845
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“PD-L1, the major ligand of PD-1, is expressed in various immune cells such as antigen-presenting cells, as well as in endothelial cells [27].”
BackgroundEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Scavenger receptors in homeostasis and immunity
Canton, J., Neculai, D., & Grinstein, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3515 · Cited by 838 · cited 2×
“One of the most extensively studied scavenger receptors on LSECs is the mannose receptor [25].”
BackgroundRole of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523 · cited 2×
“In addition, LSECs influence the composition of hepatic immune populations by distinct expression of adhesion molecules and chemokines in diseased liver, which indicates the crucial role of LSECs in immune-regulation [9].”
Background
Cited by
Sabit, H., Pawlik, T. M., Radwan, F., Abdel-Hakeem, M., Abdel-Ghany, S., Wadan, A.-H. S., Elzawahri, M., El-Hashash, A., & Arneth, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02357-z · Cited by 239
The evolving role of liver sinusoidal endothelial cells in liver health and disease
McConnell, M. J., Kostallari, E., Ibrahim, S. H., & Iwakiri, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000207 · Cited by 189
“For example, the overexpression of KLF2 in the cirrhotic rat livers through Adenovirus-Klf2 administration exerts an antifibrotic and vasoprotective effect by decreasing the portal pressure as well as increasing eNOS expression and the response to the vasodilator acetylcholine (102).”
InfluentialEndothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Nasiri-Ansari, N., Androutsakos, T., Flessa, C.-M., Kyrou, I., Siasos, G., Randeva, H. S., Kassi, E., & Papavassiliou, A. G. (2022) · Cells · doi:10.3390/cells11162511 · Cited by 131
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Multiscale biomechanics and mechanotransduction from liver fibrosis to cancer
Li, N., Zhang, X., Zhou, J., Li, W., Shu, X., Wu, Y. C., & Long, M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114448 · Cited by 102
Metadata
- Authors
- Yu, Z., Guo, J., Liu, Y., Wang, M., Liu, Z., Gao, Y., & Huang, L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Shanghai University of Traditional Chinese Medicine (CN)
- Corresponding author
- Gao, Yueqiu
- Huang, Leaf
- Venue
- Journal of Nanobiotechnology
- Published
- 2022-01-04
- Volume
- 20
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1477-3155 (ISSN-L)
- PMC
- PMC8725360
- OpenAlex
- W4205834838
- Cited by
- 114
- References
- 37
- Citations by year
- 2026: 18 · 2025: 34 · 2024: 29 · 2023: 21 · 2022: 12
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Nanobiotechnology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (CA198999)
- National Natural Science Foundation of China (82074154, 81774240)
- China Scholarship Council (201808310047)
- Shanghai Rising-Star Program (17QA1403900)
- Youth Tip-top Talent program in Shanghai
- Training Plan of Outstanding Young Medical Talents from Shanghai Municipal Health Bureau (2017YQ021)
- Siming Scholar from Shanghai Shuguang Hospital (SGXZ-201904)
- Youth Xinglin Scholar from Shanghai University of Traditional Chinese Medicine
- Jilin University
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- hepatocellular carcinoma, simvastatin, liver sinusoidal endothelial cells, hepatic stellate cells, tumor microenvironment, liver fibrosis, CXCL16, NKT cells, PD-L1 blockade, immunosuppression, stromal remodeling
- MeSH terms
- Nanoparticle Drug Delivery System, Animals, Cells, Cultured, Carcinoma, Hepatocellular, Humans, Liver, Liver Neoplasms, Male, Mice, Inbred C57BL, Signal Transduction, Simvastatin, Endothelial Cells, Mice, Nanoparticles, Hepatic Stellate Cells, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1186/s12951-021-01205-8
- The paper
- Yu, Z., Guo, J., Liu, Y., Wang, M., Liu, Z., Gao, Y., & Huang, L. (2022). Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-021-01205-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.